Patents by Inventor David Bumcrot

David Bumcrot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for inhibiting expression of TMPRSS6 gene
    Patent number: 12559755
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6.
    Type: Grant
    Filed: September 28, 2023
    Date of Patent: February 24, 2026
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: David Bumcrot, Brian Bettencourt, Ivanka Toudjarska
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE
    Publication number: 20240309386
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6.
    Type: Application
    Filed: September 28, 2023
    Publication date: September 19, 2024
    Inventors: David Bumcrot, Brian Bettencourt, Ivanka Toudjarska
  • SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT
    Publication number: 20240255880
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina1.
    Type: Application
    Filed: August 29, 2023
    Publication date: August 1, 2024
    Inventors: Alfica Sehgal, David Bumcrot, Brian Bettencourt
  • GNAQ targeted dsRNA compositions and methods for inhibiting expression
    Patent number: 12031133
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: July 9, 2024
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • Therapeutic compositions
    Patent number: 11530408
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: December 20, 2022
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Bumcrot
  • GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression
    Publication number: 20220348915
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Application
    Filed: February 9, 2021
    Publication date: November 3, 2022
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • ASSAYS AND METHODS FOR DETERMINING ACTIVITY OF A THERAPEUTIC AGENT IN A SUBJECT
    Publication number: 20220307083
    Abstract: The invention relates to methods and assays for determining the activity of a composition comprising a therapeutic gene administered to a subject.
    Type: Application
    Filed: February 14, 2022
    Publication date: September 29, 2022
    Inventors: Dinah Sah, David Bumcrot, Alfica Sehgal
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE
    Publication number: 20220251570
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6.
    Type: Application
    Filed: October 26, 2021
    Publication date: August 11, 2022
    Inventors: David Bumcrot, Brian Bettencourt, Ivanka Toudjarska
  • SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT
    Publication number: 20220155716
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina1.
    Type: Application
    Filed: October 5, 2021
    Publication date: May 19, 2022
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica SEHGAL, David BUMCROT, Brian BETTENCOURT
  • Compositions and methods for inhibiting expression of TMPRSS6 gene
    Patent number: 11198876
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: December 14, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: David Bumcrot, Brian Bettencourt, Ivanka Toudjarska
  • GNAQ targeted dsRNA compositions and methods for inhibiting expression
    Patent number: 10954516
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: March 23, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • Serpina1 siRNAs: compositions of matter and methods of treatment
    Patent number: 10935917
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina 1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina 1.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: March 2, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica Sehgal, David Bumcrot, Brian Bettencourt
  • SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT
    Publication number: 20210041823
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina1.
    Type: Application
    Filed: October 26, 2020
    Publication date: February 11, 2021
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica SEHGAL, David BUMCROT, Brian BETTENCOURT
  • THERAPEUTIC COMPOSITIONS
    Publication number: 20200255833
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Application
    Filed: April 22, 2020
    Publication date: August 13, 2020
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, David BUMCROT
  • Therapeutic compositions
    Patent number: 10669544
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: June 2, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Bumcrot
  • SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT
    Publication number: 20190354055
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpinal gene, and methods of using such dsRNA compositions to inhibit expression of Serpinal.
    Type: Application
    Filed: July 17, 2019
    Publication date: November 21, 2019
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica Sehgal, David Bumcrot, Brian Bettencourt
  • THERAPEUTIC COMPOSITIONS
    Publication number: 20190264207
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Application
    Filed: March 14, 2019
    Publication date: August 29, 2019
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, David BUMCROT
  • Therapeutic compositions
    Patent number: 10273477
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: April 30, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Bumcrot
  • GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression
    Publication number: 20190106694
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Application
    Filed: April 3, 2018
    Publication date: April 11, 2019
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • GNAQ targeted dsRNA compositions and methods for inhibiting expression
    Patent number: 9963700
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: May 8, 2018
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot